MARSI BIONICS SL

Their core work

MARSI BIONICS is a Spanish medical robotics SME that designs and develops wearable exoskeleton systems for rehabilitating people with chronic ambulatory disabilities — conditions that permanently or severely impair walking. Their work sits at the intersection of biomechanical engineering, robotics, and clinical rehabilitation: they translate gait mechanics into powered assistive devices that help patients regain mobility. They have moved from early market validation (e-walk) to a full-scale product development program (MARSI project) funded under the EU's most competitive SME instrument. Their real-world output is hardware — robotic walking systems — aimed at clinical and home rehabilitation markets.

What they specialise in

How they've shifted over time

MARSI BIONICS has a short but sharply focused trajectory. Their first project (e-walk, 2017–2018) was a small coordination and support action — effectively a market feasibility and business development exercise around biomechanical robotic healthcare. That was rapidly followed by the MARSI project (2018–2021), a major SME Instrument Phase 2 grant (EUR 1.64M) dedicated to full product development for chronic ambulatory rehabilitation. The shift from a EUR 103K market study to a EUR 1.64M product development program within one year indicates a company that completed market validation quickly and moved straight into scaling. There is no evidence of sector drift — their focus has remained tightly on medical walking-assistance robotics throughout their H2020 participation.

MARSI BIONICS is on a commercialization trajectory — having validated the market and secured large-scale EU product development funding, their next logical step is clinical trials, regulatory clearance (MDR), and market entry in the powered exoskeleton space.

How they like to work

MARSI BIONICS always leads — both of their H2020 projects were coordinated by them, not joined as partners. Their consortium footprint is minimal: only one unique partner across two projects, in a single country, suggesting they prefer tight, controlled collaborations over broad multi-partner consortia. This is characteristic of product-focused SMEs that protect IP and keep decision-making close — potential collaborators should expect to engage with them as a technology provider or integration partner rather than as an equal consortium co-designer.

Their H2020 network is extremely compact — just one unique partner across two projects, all within a single country (Spain). They have not built a broad European research network, which is consistent with an SME focused on proprietary product development rather than collaborative research dissemination.

What sets them apart

MARSI BIONICS occupies a specific niche within medical robotics: they focus on chronic ambulatory disability — a harder and less glamorous target than acute stroke recovery, but a much larger unmet clinical need. Their successful SME Instrument Phase 2 grant (one of the most competitive in H2020, with a roughly 5% acceptance rate) signals that the European Commission's evaluators judged their technology and business case as genuinely viable. For a consortium builder in digital health, assistive technology, or neurorehabilitation, they bring something rare: a Spanish SME with an actual hardware product in development, not just a research prototype.

Highlights from their portfolio

• MARSI
  Awarded EUR 1.64M under the highly competitive SME Instrument Phase 2 — the EU's flagship scale-up grant — making it one of the largest single grants available to an SME and a strong signal of commercial viability validated by independent expert reviewers.
• e-walk
  Functioned as the market validation stepping stone that preceded the larger MARSI grant, demonstrating a disciplined phased approach to product development that is uncommon among early-stage hardware SMEs.